The trend toward personalized medicine is growing: more and more innovative drugs depend on upfront diagnoses from biomarkers to ensure safe and effective therapy. Thus, the search for viable markers has become an increasingly integral part of modern drug development.
Thanks to our collaboration with Dr. Regenold, we can support the (co-)development of Companion Diagnostics (CDx) for both developers of diagnostics as well as pharmaceutical companies. Having access to a vast network of partners and clients also enables us to identify potential partners for CDx development.
For more information, visit us at: www.ceplus.eu